

**Editor**

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 9.270

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2015 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Teichset and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.
Register using this QR code.

Editorial

- 793** The therapeutic window of opportunity in rheumatoid arthritis: does it ever close?
K Raza, A Filer

Viewpoint

- 795** Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity
M Hughes, J B Lilleker, A L Herrick, H Chinoy

Criteria

- 799** Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers
S Federici, M P Sormani, S Ozen, H J Lachmann, G Amaryan, P Woo, I Koné-Paut, N Dewarriat, L Cantarini, A Insalaco, Y Uziel, D Rigante, P Quartier, E Demirkaya, T Herlin, A Meini, G Fabio, T Kallinich, S Martino, A Y Butbul, A Olivieri, J Kuemmerle-Deschner, B Neven, A Simon, H Ozdogan, I Touitou, J Frenkel, M Hofer, A Martini, N Ruperto, M Gattorno, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Eurofever Project

Clinical and epidemiological research

- 806** Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts
J A B van Nies, R Tsonaka, C Gaujoux-Viala, B Faurel, A H M van der Helm-van Mil
- 813** Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis
L Eder, A Thavaneswaran, V Chandran, R J Cook, D D Gladman
- 818** Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)
C O Bingham III, W Rizzo, A Kivitz, A Hassanali, R Upmanyu, M Kleerman
- 823** Enthesitis in patients with psoriatic arthritis, axial spondyloarthritis and healthy subjects assessed by 'head-to-toe' whole-body MRI and clinical examination
R P Poggenborg, I Eshed, M Østergaard, I J Sørensen, J M Møller, O R Madsen, S J Pedersen
- 830** Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS
U Kiltz, D van der Heijde, A Boonen, A Cieza, G Stucki, M A Khan, W P Malesymowych, H Marzo-Ortega, J Reveille, S Stebbings, C Bostan, J Braun
- 836** Impact of allopurinol on risk of myocardial infarction
L Grimaldi-Bensouda, A Alperovich, E Aubrun, N Danchin, M Rossignol, L Abenham, P Richette, the PGRx MI Group
- 843** Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
J S Smolen, P Emery, G F Ferraccioli, W Samborski, F Berenbaum, O R Davies, W Koets, O Purcaru, B Bennett, H Burkhart
- 851** Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens
M Fransen, M Agaliois, L Naim, M Votrubec, L Bridgett, S Su, S Jan, L March, J Edmonds, R Norton, M Woodward, R Day, on behalf of the LEGS study collaborative group
- 859** Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)
R Seror, E Theander, J G Brun, M Ramos-Casals, V Valim, T Dörner, H Bootsma, A Tzioufas, R Solans-Laqué, T Mandl, J-E Gottenberg, E Hachulla, K L Sivils, W-F Ng, A-L Fauchais, S Bombardieri, G Valesini, E Bartoloni, A Saraux, M Tomsic, T Sumida, S Nishiyama, R Caporali, A A Kruize, C Vollenweider, P Ravaut, C Vitali, X Mariette, S J Bowman, on behalf of the EULAR Sjögren's Task Force
- 867** A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial
M B Axelsen, I Eshed, K Horslev-Petersen, K Stengaard-Pedersen, M L Heiland, J Møller, P Junker, J Pødenphant, A Schlemmer, T Ellingsen, P Ahlquist, H Lindgaard, A Linauskas, M Y Dam, I Hansen, H C Horn, C G Ammitzøll, A Jørgensen, S B Krintel, J Raun, N S Krogh, J S Johansen, M Østergaard, OPERA study group
- 876** Predicting the severity of joint damage in rheumatoid arthritis: the contribution of genetic factors
H W van Steenberg, R Tsonaka, T WJ Huizinga, S le Cessie, A H M van der Helm-van Mil
- 883** Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis
J A B van Nies, H W van Steenberg, A Krabben, W Stomp, T WJ Huizinga, M Rejnjerse, A H M van der Helm-van Mil
- 890** Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
K Chatzidionysiou, J Askeling, J Eriksson, L E Kristensen, R van Vollenhoven, for the ARTIS group
- 897** The specificity of ultrasound-detected bone erosions for rheumatoid arthritis
A S Zayat, K Ellegaard, P G Conaghan, L Terslev, E M A Hensor, J E Freeston, P Emery, R J Wakefield

MORE CONTENTS ►

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme.
See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

COPE COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



- 904** Recent infections are associated with decreased risk of rheumatoid arthritis: a population-based case-control study
M E C Sandberg, C Bengtsson, L Klareskog, L Alfredsson, S Saevarsdottir

- 908** Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study
N Dalbeth, M E House, O Aati, P Tan, C Franklin, A Home, G D Gamble, L K Stamp, A J Doyle, F M McQueen

Basic and translational research

- 912** Autophagy is activated in systemic lupus erythematosus and required for plasmablast development
A J Clarke, U Ellinghaus, A Cortini, A Stranks, A K Simon, M Botto, T J Vyse

- 921** Angiogenic T cells are decreased in rheumatoid arthritis patients
J Rodríguez-Carrio, M Alperi-López, P López, S Alonso-Castro, F J Ballina-García, A Suárez

- 928** Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis
L Yeo, H Lom, M Juarez, M Snow, C D Buckley, A Filer, K Raza, D Scheel-Toellner

- 936** Inhibition of casein kinase II reduces TGF β induced fibroblast activation and ameliorates experimental fibrosis
Y Zhang, C Dees, C Beyer, N-Y Lin, A Distler, P Zerr, K Palumbo, L Susok, A Kreuter, O Distler, G Schett, J H W Distler

- 944** Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease
E L Culver, E Vermeulen, M Makuch, A van Leeuwen, R Sadler, T Cargill, P Klenerman, R C Aalberse, S M van Ham, E Barnes, T Rispen

Letters

- 948** Unifocal psoriatic arthritis development in identical twins following site specific injury: evidence supporting biomechanical triggering events in genetically susceptible hosts
J Ng, A L Tan, D McGonagle

- 949** Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system
J N Stoop, A Fischer, S Hayer, M Hegen, T WJ Huizinga, G Steiner, L A Trouw, R EM Toes

Correction

- 920** Correction

Electronic pages

Correspondence

- e33** Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?
M Boers

- e34** Response to: 'Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr Boers
C Roubille, V Richer, T Starnino, C McCourt, A McFarlane, P Fleming, S Siu, J Kraft, C Lynde, J Pope, W Gulliver, S Keeling, J Dutz, L Bessette, R Bissonnette, B Haraoui

- e35** Does MOVES move the needle?
R Meyer

- e36** Response to: 'Does MOVES move the needle?' by Dr Meyer
M C Hochberg, on behalf of the MOVES Investigation Group

- e37** Is chondroitin sulfate plus glucosamine superior to placebo in the treatment of knee osteoarthritis?
C Zeng, J Wei, G-h Lei